MiMedx Group (MDXG) Projected to Post Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to issue its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect MiMedx Group to post earnings of $0.07 per share and revenue of $94.7350 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The firm had revenue of $67.69 million for the quarter. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

Shares of MDXG stock opened at $6.73 on Tuesday. The company has a market capitalization of $995.77 million, a PE ratio of 32.05 and a beta of 1.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. The firm’s 50-day moving average is $6.98 and its two-hundred day moving average is $6.77. MiMedx Group has a 12 month low of $5.69 and a 12 month high of $10.14.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald lifted their price target on shares of MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors have recently modified their holdings of the business. SkyView Investment Advisors LLC increased its holdings in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after purchasing an additional 3,032 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares in the last quarter. AQR Capital Management LLC increased its position in shares of MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of MiMedx Group by 57.2% during the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after purchasing an additional 4,708 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in MiMedx Group by 3.2% during the 2nd quarter. Rhumbline Advisers now owns 182,858 shares of the company’s stock worth $1,117,000 after buying an additional 5,702 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.